 <h1>Zyflo CR Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>zileuton</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about zileuton. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Zyflo CR.</p><h2>In Summary</h2><p><b>More frequent side effects include:</b> dyspepsia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to zileuton: oral tablet, oral tablet extended release</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, zileuton (the active ingredient contained in Zyflo CR) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking zileuton:</p><p>
<i>Rare</i>
</p><ul>
<li>Flu-like symptoms</li>
<li>itching</li>
<li>right upper stomach pain</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Attack, assault, or force</li>
<li>attempts at killing oneself</li>
<li>discouragement</li>
<li>dry mouth</li>
<li>fear or nervousness</li>
<li>feeling sad or empty</li>
<li>hyperventilation</li>
<li>irregular heartbeats</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>restlessness</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>shakiness in the legs, arms, hands, or feet</li>
<li>shortness of breath</li>
<li>sleeplessness</li>
<li>tiredness</li>
<li>trembling or shaking of the hands or feet</li>
<li>trouble with concentrating</li>
<li>trouble with sleeping</li>
<li>unable to sleep</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of zileuton may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Cough</li>
<li>fever</li>
<li>headache</li>
<li>nausea</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>stuffy or runny nose</li>
<li>tightness of the chest or wheezing</li>
<li>troubled breathing</li>
<li>upset stomach</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>sore throat</li>
<li>weakness</li>
</ul><p>
<!-- end oral tablet, oral tablet extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zileuton: oral tablet, oral tablet extended release</i></p><h3>General</h3><p>The most commonly occurring adverse reactions are sinusitis, nausea, and pharyngolaryngeal pain.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 24.6%)</p>
<p><b>Common</b> (1% to 10%): Hypertonia, nervousness, dizziness, somnolence<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, urticaria<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Dyspepsia (8.2%), nausea (5.5%), diarrhea (5%), abdominal pain, upper abdominal pain, vomiting, constipation, flatulence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, vaginitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The WBC counts returned to normal or baseline following discontinuation of this drug.  The clinical significance of these findings is not known.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Low white blood cell count (2.6%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatotoxicity, ALT elevations (1.8%)</p>
<p><b>Postmarketing reports</b>: Hepatic injury, including death, life-threatening liver injury with recovery, symptomatic jaundice, hyperbilirubinemia, and elevations of ALT more than 8 times ULN<sup>[Ref]</sup></p><p>The majority of ALT elevations (82%) were reported within the first 3 months of treatment and resolved within 21 days for most of these patients after discontinuation of the drug.  In the extended release group, the majority of ALT elevations (60%) occurred in the first month of treatment; in a few patients, the levels returned to less than 2 times ULN or normal within 9 and 12 days.</p>
<p>The hepatic function enzyme elevations did not result in any cases of jaundice, development of chronic liver disease, or death in this clinical trial.  In patients who discontinued this drug, ALT levels dropped below 2 times ULN in approximately one month.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity, rash<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Lymphadenopathy<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia (7%), arthralgia, neck pain/rigidity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pain (7.8%), asthenia (3.8%), accidental injury (3.4%), fever, malaise<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Postmarketing reports</b>: Sleep disorders, behavior changes<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infections (9%), sinusitis (6.5%), pharyngolaryngeal pain (5%), chest pain<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Zyflo CR (zileuton)." Cornerstone Therapeutics, Cary, NC. </p><p id="ref_2">2. "Product Information. Zyflo (zileuton)." Abbott Pharmaceutical, Abbott Park, IL. </p><p id="ref_3">3. Hackshaw KV, Shi Y, Brandwein SR, Jones K, Westcott JY "A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus." J Rheumatol 22 (1995): 462-8</p><p id="ref_4">4. Weinblatt ME, Kremer JM, Coblyn JS, Helfgott S, Maier AL, Petrillo G, Henson B, Rubin P, Sperling R "Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis." J Rheumatol 19 (1992): 1537-41</p><p id="ref_5">5. "Product Information. Zylo Filmtab (zileuton)." Abbott Pharmaceutical, Abbott Park, IL. </p><p id="ref_6">6. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, et al "The effect of inhibition of 5-lipoxygenase by zileuton in mild-to- moderate asthma." Ann Intern Med 119 (1993): 1059-66</p><p id="ref_7">7. Israel E, Cohn J, Dube L, Drazen JM "Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group." JAMA 275 (1996): 931-6</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Zyflo CR (zileuton)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: leukotriene modifiers</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zyflo CR &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Zyflo</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Asthma, Maintenance</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zileuton: oral tablet, oral tablet extended release</i></p><h3>General</h3><p>The most commonly occurring adverse reactions are sinusitis, nausea, and pharyngolaryngeal pain.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 24.6%)</p><p><b>Common</b> (1% to 10%): Hypertonia, nervousness, dizziness, somnolence<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, urticaria<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Dyspepsia (8.2%), nausea (5.5%), diarrhea (5%), abdominal pain, upper abdominal pain, vomiting, constipation, flatulence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, vaginitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The WBC counts returned to normal or baseline following discontinuation of this drug.  The clinical significance of these findings is not known.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Low white blood cell count (2.6%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatotoxicity, ALT elevations (1.8%)</p><p><b>Postmarketing reports</b>: Hepatic injury, including death, life-threatening liver injury with recovery, symptomatic jaundice, hyperbilirubinemia, and elevations of ALT more than 8 times ULN<sup>[Ref]</sup></p><p>The majority of ALT elevations (82%) were reported within the first 3 months of treatment and resolved within 21 days for most of these patients after discontinuation of the drug.  In the extended release group, the majority of ALT elevations (60%) occurred in the first month of treatment; in a few patients, the levels returned to less than 2 times ULN or normal within 9 and 12 days.</p><p>The hepatic function enzyme elevations did not result in any cases of jaundice, development of chronic liver disease, or death in this clinical trial.  In patients who discontinued this drug, ALT levels dropped below 2 times ULN in approximately one month.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity, rash<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Lymphadenopathy<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia (7%), arthralgia, neck pain/rigidity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pain (7.8%), asthenia (3.8%), accidental injury (3.4%), fever, malaise<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Postmarketing reports</b>: Sleep disorders, behavior changes<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infections (9%), sinusitis (6.5%), pharyngolaryngeal pain (5%), chest pain<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Zyflo CR (zileuton)." Cornerstone Therapeutics, Cary, NC. </p><p id="ref_2">2. "Product Information. Zyflo (zileuton)." Abbott Pharmaceutical, Abbott Park, IL. </p><p id="ref_3">3. Hackshaw KV, Shi Y, Brandwein SR, Jones K, Westcott JY "A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus." J Rheumatol 22 (1995): 462-8</p><p id="ref_4">4. Weinblatt ME, Kremer JM, Coblyn JS, Helfgott S, Maier AL, Petrillo G, Henson B, Rubin P, Sperling R "Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis." J Rheumatol 19 (1992): 1537-41</p><p id="ref_5">5. "Product Information. Zylo Filmtab (zileuton)." Abbott Pharmaceutical, Abbott Park, IL. </p><p id="ref_6">6. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, et al "The effect of inhibition of 5-lipoxygenase by zileuton in mild-to- moderate asthma." Ann Intern Med 119 (1993): 1059-66</p><p id="ref_7">7. Israel E, Cohn J, Dube L, Drazen JM "Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group." JAMA 275 (1996): 931-6</p><h2>More about Zyflo CR (zileuton)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: leukotriene modifiers</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zyflo CR &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Asthma, Maintenance</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>